TAIWANPLUS
1.12.2021 08:41:10 CET | Business Wire | Press release
TaiwanPlus, a new global English-language video streaming service, has launched a Taiwan Cinema program with a selection of ten films that exemplify the diversity of Taiwan’s culture, peoples, and history. The most prominent collection is Ang Lee’s 'Father Knows Best' trilogy. Notably, this is the first time the films are available to be streamed online together. Director Lee’s strength in bringing together family members to create tension and tender comedic moments shine in this trio of PUSHING HANDS (1991), EAT DRINK MAN WOMAN (1994), and THE WEDDING BANQUET (1993).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211130006205/en/
Renowned actor Sihung Lung acts as the consummate traditional Taiwanese father in roles that evoke the sweet bitterness of an aging man trying to bring each casts’ family together. Hailed for their unrestrained portrayals of Eastern family dynamics, the collection is available for free until December 31, 2021 to global viewers outside of the United States, Canada, Mexico, Germany, and France at TaiwanPlus.com via the website’s new Cinema section and downloadable TaiwanPlus mobile app.
In addition, seven other films will be presented until December 31, 2021 that will take viewers back to some of Taiwan’s greatest films outside of the Taiwan New Cinema Wave. “Movies are the best way to convey culture and emotions. Through these ten films of different eras and themes, we provide the audience a window into Taiwan’s culture and diversity.” says Joanne Tsai, TaiwanPlus CEO.
In addition to Ang Lee’s renowned films, the program is showcasing films directed by Chung Mong-hong, who recently won Best Narrative Feature and Best Original Screenplay for THE FALLS (2021) at this year's Golden Horse Awards. The After Death duo that brings us to edgier contemporary Taiwanese films that dare to dive into darker narratives. THE FOURTH PORTRAIT (2010) follows the story of a son left behind after the death of his father while in SOUL (2013), the mysterious collapse of a young chef leads to a terrifying spiritual possession in the mountains.
A trio of restored films include two cult favorite black and white films from the Taiwan Hollywood era of the 1960s-- THE FANTASY OF DEER WARRIOR (1961) and VENGEANCE OF THE PHOENIX SISTERS (1968) along with WHEEL OF LIFE (1983), an anthology helmed by King Hu that features three main characters reincarnating into the same twisted love triangle in each segment.
Rounding out the series are two documentaries. In SMALL TALK (2016) by Huang Hui-chen, a 20 year film in the making where the filmmaker attempts to confront and reconcile painful past memories with her mother, a lesbian Taoist priestess. Meanwhile, in ARCHIVING TIME (2019), viewers follow a group of film preservation staff from the Taiwan Film and Audiovisual Institute as they work to preserve crumbling reels of film the world has yet to see.
Watch Free @https://tw.plus/twxgh
View source version on businesswire.com: https://www.businesswire.com/news/home/20211130006205/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom